ï¼åèï¼STAPç´°èè«æã¾ã¨ãâNature Articleè«æ
â»æ¢ã«æ¤åãããArticleè«æã§ãããå
ã«UPããçç ã®èª¿æ»å ±åæ¸ãç解ããä¸ã§ã®åèç¨ã«ãSTAPç´°èã®ä¸»è«æã§ãã£ããã®è«æå
容ãã¾ã¨ãããã®ãUPãã¦ããã¾ãã
ï¼EDã¨ç¥ãã¦ããã®ã¯ãExtended Data Figureï¼
Stimulus-triggered fate conversion of somatic cells into pluripotency
http://www.nature.com/nature/journal/v505/n7485/full/nature12968.html
Haruko Obokata, Teruhiko Wakayama, Yoshiki Sasai, Koji Kojima, Martin P. Vacanti, Hitoshi Niwa, Masayuki Yamato & Charles A. Vacanti
Author Contributions
å°ä¿æ¹æ´åã 笹äºè³æ¨¹ å稿ãå·ç.
å°ä¿æ¹æ´åãè¥å±±ç
§å½¦ã笹äºè³æ¨¹ å®é¨ã®å®æ½
å°å³¶å®å¸ã¯ãå°ä¿æ¹æ´åã®ç§»æ¤å®é¨ãè£å©
å°ä¿æ¹æ´åãè¥å±±ç
§å½¦ã笹äºè³æ¨¹ã丹羽ä»å²ããã£ã¼ã«ãºã»ãã«ã³ã㣠ããã¸ã§ã¯ãã®ãã¶ã¤ã³
ãã¼ãã£ã³ã»ãã«ã³ãã£ã大åé
ä¹ ããã¸ã§ã¯ãã®ãã¶ã¤ã³ã¨è©ä¾¡ãè£å©
Received 10 March; accepted 20 December 2013.ãRetraction July, 2014.
â»CD45=ç½è¡çã«å
±éããæå
â»Oct4=å¤è½æ§ã«é¢é£ãããã¼ã«ã¼
Low pH triggers fate conversion in somatic cells
ã»Oct4-gfpãéºä¼åå°å
¥ããçå¾1é±éã®C57BL/6ãã¦ã¹ã®ãªã³ãçãã©ã¯ã·ã§ã³ããCD45+ç´°èãFACSã§ã½ã¼ãããè²ã
ãªãå¼·ãä¸æçãªç©ççã»ç§å¦çåºæ¿ã«æããã
ããããããããããããããâ
ã»ãããã®CD45+ç´°èãç½è¡ç
é»å®³å åï¼LIFï¼ã¨B27ãæ·»å ããDMEM/F12 å¹å°ï¼LIF+B27å¹å°ï¼ã«æ¸æ¿ãã¦ããæ°æ¥éå¾ã®Oct4ããã¢ã¼ã¿ã¼ã®æ´»æ§åã調ã¹ãã
ã»ï¼ã¤ã®çç±ãããä½pHã«ããç°å¢å¤åã«ç¹ã«èå³ããã£ãã
ï¼ï¼ä½pHå¦çãOct4ã®èªå°ã«æãå¹æçã§ãã£ãã
ï¼ï¼å¤å
¸çãªå®é¨ççºçå¦ã§ã¯ããäºè´æ»æ§ãã®æ¡ä»¶ä¸ã§ä¸æçãªä½pHå¦çãããã¨ãçµç¹ã®ååç¶æ
ãå¤ãããããpH6.0æªæºã®ã¯ã¨ã³é
¸ãã¼ã¹ã®é
¸æ§å¹å°ã«æµ¸ããã¨ã§ããµã©ãã³ãã¼ã®åç©æ¥µããå¶çºçã«ç¥çµè»¢æãèµ·ãããã¨ã以åãã示ããã¦ããã
ã»åºæ¿ç¡ãã§ã¯ãLIF+B27å¹å°ã§ã®å¹é¤æéã«é¢ä¿ãªããCD45ã§ã½ã¼ãããOct4-GFPãçºç¾ããç´°èã¯ç¡ãã£ãã
ã»å¯¾ç §çã«ãä½pHå¹å°ã§30åéå¦çï¼25åéã¤ã³ãã¥ãã¼ããã¦5åéé å¿ãæãå¹æçãªã®ã¯pH5.4ã5.8ï¼ããã¨ãããªãã®æ°ã®çç¶ã®éåä½ãLIF+B27å¹å°ã«ç¾ããå¹é¤7æ¥å¾ã«ã¯Oct4-GFPãçºç¾ãããFig. 1a, ED. 1a / Fig. 1b
ã»æ°çä»ã®è¾èç´°èã§è¡ã£ãå ´åãå ¨ã¦ã®ã±ã¼ã¹ã§ããªãã®æ°ã®GFPï¼ç´°èãç¾ãããï¼n=30ï¼
ï½¥CD45+ç´°èããã®Oct4-GFP+ç´°èã®åºç¾ã¯ãããã¼ãµã¤ãã¡ããªã¼ã§ã観å¯ãããã
Fig. 1c, ED. 1b, c
ã»CD45+ç´°èãCD90 (Tç´°è)ã»CD19 (Bç´°è)ã»CD34(é è¡åé§ç´°è)ã«å¯¾ãã¦é½æ§ã¨é°æ§ã®éå£ã«ãã©ã¯ã·ã§ã³åããã¦ããããã«ä½pHå¦ç
ãããããããããããããâ
ã»CD34+ã®é è¡åé§ç´°èãé¤ãTç´°èã¨Bç´°èãå«ããã©ã¯ã·ã§ã³ã®ç´°èã¯ãCD45+ç´°èã«ãã©ã¯ã·ã§ã³ãããªãã£ãç´°èã¨æ¯ã¹ã¦ãOct4-GFP+ç´°èãå¹ççã«ç£çãããï¼7æ¥å¾ã«çåãã¦ããç´°èã®25ã50%ï¼CD34+ç´°èã¯ãOct4-GFP+ç´°èãã»ã¨ãã©ç£çããªãã£ããï¼<2%ï¼ED. 1d
ã»å¤è½æ§ç´°èã®ç¶æå¹å°ã®ä¸ã§ã¯ãLIF+B27å¹å°ãæãOct4-GFP+ç´°èã®åºç¾ãé«ããèç¤èä¸å±¤ç±æ¥å¹¹ç´°è(EpiSC)å¹å°ã§ã¯åºç¾ããªãã£ããED. 1e
ã»å¹é¤ãã¦ãã0ã2æ¥ã§ã®LIFã®åå¨ã®æç¡ã¯7æ¥å¾ã®Oct4-GFP+ç´°èã®ç£çã«ãã»ã©å½±é¿ããªããã4ã7æ¥ã§ã®LIFã®æ·»å ã§ã¯ä¸ååã§ãããã¨ãããLIFã¸ã®ä¾åã¯å¹é¤éå§ãã2ã4æ¥ã«ã¹ã¿ã¼ããããã¨ã示ãã¦ãããED. 1f
ã»1æ¥å¾ã§ã®çåç´°èã®ã»ã¨ãã©ã¯ãã¾ã CD45+ãã¤Oct4-GFPâã§ãã£ãã
ããããããããããããããâ
ã»3æ¥å¾ã«ã¯ãç´°èã®ç·æ°ã1/3ãã1/2ã«æ¸ããæ¯è¼çå¼±ãã·ã°ãã«å¼·åº¦ã§ã¯ããããããªãã®çåç´°èãOct4-GFPï¼ã¨ãªã£ããFig. 1d, ED. 1g, h / Fig. 1d
ããããããããããããããâ
ã»7æ¥å¾ã«ã¯ãOct4-GFPâCD45âç´°èã¨ã¯ç°ãªããããªãã®æ°ã®Oct4-GFPï¼CD45âç´°è(çåç´°èã®1/2ã2/3)ãæ§æããããFig. 1c, Fig. 1d
ã»åæ§ã«å¹é¤ããä½pHå¦çãããªãCD45+ ç´°èã«ã¯ãOct4-GFPï¼CD45âã®éå£ã¯ã¯ã£ããã¨ç¾ããªãã£ããFig. 1c
ã»æªå¦çã®ç´°èã«ã¯è¦³å¯ãããªãããä½pHå¦çããCD45+ ç´°èã¯ãæåã®æ°æ¥éã«æ¬¡ç¬¬ã«GFPã·ã°ãã«ãåºã¦ããããã®ä¸æ¹ãOct4-GFPãçºç¾ããç´°èã®CD45ã®å
ç«æ´»æ§ã¯æ¬¡ç¬¬ã«æ¸ã£ã¦ãã£ããFig. 1e, ED. 2a / Fig. 1f, ED. 2b
ããããããããããããããâ
ã»5æ¥å¾ã¾ã§ã«ãOct4-GFP+ç´°èã¯äºãã«ä»çããççã«ããéå£ãå½¢æããããããã®GFP+éå£ã¯åããæ´»çºã§ãåãã¦ããæã«ç´°èçªèµ·ãåºããã¨ãå¤ãã
ã»Oct4-GFP+ç´°èã¯ãç´°è質ãå°ãªãã¦ãµã¤ãºãå°ãããå ã®CD45+ãªã³ãçã¨æ¯ã¹ã¦æçãªæ ¸æ§é ã示ãããFig. 1g
ã»7æ¥å¾ã®Oct4-GFP+ç´°èã¯ãä¸è¬çã«å°ããã¨è¦ãªããã¦ããæªå¦çã®CD45+ç´°èãESç´°èãããå°ããã£ããFig. 1g, h, ED. 2c
ã»ä½pHå¦çCD45+ç´°èã®ç´å¾ã¯ãOct4-GFPãçºç¾ããåã®æåã®2æ¥éã§æ¸å°ãã¯ããããFig. 1f
ã»GFPçºç¾ã®éå§ã«ã¯ç´°èåè£ãä¼´ããªãã£ãããããã¯ã¹ãã¬ã¹ãä¸ããå¾ã®Oct4-GFP+ç´°èã§5-ethynyl-2'-deoxyuridine (EdU)ã®åãè¾¼ã¿ã観å¯ãããªãäºã¨ä¸è´ãã¦ããã
ãED. 2d
â»EdUã¯DNAã®æ§æè¦ç´ ã§ããdTï¼deoxythymidineï¼ã®ãããã¯ã§ãæ ¸å
ã®DNAã«åãè¾¼ã¾ãã
ã»å¢æ®è½åãããªãæ¬ ãã¦ãããã¨ã¯ãCD45âã®ç´°èã«æ¥µããããªCD45+ ç´°èãã³ã³ã¿ããã¦ãã¦ããããä½pHå¦çãã¦æåã®æ°æ¥ã§æ¥éã«å¢ãã¦ç¸å½ãªOct4-GFP+éå£ãå½¢æããã®ã§ã¯ãªããã¨ããå¯è½æ§ã¸ã®å証ã«ãªã£ã¦ããã
ã»Tcrb (Tç´°èå容ä½éºä¼å)ã®ã²ãã åæ§æããFACS精製ããCD45+ ç´°èã¨CD90ï¼CD45ï¼Tç´°èç±æ¥ã®Oct4-GFP+ç´°èã§è¦³å¯ããããã¨ã¯ãå°ãªãã¨ã系統ã«é¢ä¿ä»ããããTç´°èã®å¯ä¸ããããã¨ã示ãã¦ãããFig. 1i, ED. 2e-gãããããããããããããããâ
â»Oct4-GFP+ç´°èã¯ãåãªãã¹ãã¬ã¹èæ§ç´°èãé¸å¥ãããã®ã§ã¯ãªããåæåã«ãã£ã¦ä½pHå¦çããCD45+ é è¡ç´°èããæ°ããä½ãããã¨çµè«ããã
Low-pH-induced Oct4ï¼cells have pluripotency
ã»7æ¥å¾ã«ãOct4-GFPï¼ã®çç¶å¡ã¯å¤è½æ§ã«é¢ãããã¼ã«ã¼ã¿ã³ãã¯è³ª(Oct4, SSEA1, Nanog, E-cadherin)ã¨ãã¼ã«ã¼éºä¼å(Oct4, Nanog, Sox2, Ecat1 (å¥åKhdc3), Esg1 (Dppa5a), Dax1 (Nrob1) and Rex1 (Zfp42))ãESç´°èã«è¦ãããã®ã«å¹æµããç¨åº¦ã§çºç¾ãããFig. 2a / Fig. 2b , ED. 3a
ã»ãããã®å¤è½æ§ãã¼ã«ã¼éºä¼åã®ç©ãããªã¬ãã«ã®çºç¾ã3æ¥å¾ã«è¦³å¯ãããã
ãFig. 2b, ED. 3b
ã»7æ¥å¾ã§ã¯è¦ãããªããã3æ¥å¾ã®Oct4-GFP+ç´°èãFlk1 (å¥åKdr) ãTal1ã®æ§ãªåæã®é è¡æ§ãã¼ã«ã¼éºä¼åãçºç¾ããäºã¯ã3æ¥å¾ã®Oct4-GFP+ç´°èã®éå£ã¬ãã«ã§ã®ãããã®çºç¾ãã¿ã¼ã³ããããã¨ãã¾ã 転æã®ãã¤ãããã¯ãªéç¨ã®ä¸ã«ãããã¨ã示ãã¦ãããED. 3c
ã»7æ¥å¾ã§ã¯ãCD45+ ç´°èã¨ESç´°èã¨ã¯ç°ãªããä½pHå¦çã§èªå°ããOct4-GFP+ç´°èã§ã¯Oct4 㨠Nanogã®ããã¢ã¼ã¿ã¼é åãåºç¯å²ã§è±ã¡ãã«åããã¦ããããããã¯å¤è½æ§ã«ã¤ãã¦ãããã®éµã¨ãªãéºä¼åã§ã¨ãã¸ã§ããã£ãã¯ãªåããã°ã©ã åãããªãé²è¡ãã¦ãããã¨ã示ãã¦ãããFig. 2c
ã»çä½å¤ã§ã®åå試é¨ã§ã¯ãå
èã®å
èèæ§ä¸ç®ã¨åæ§ã«ãä½pHå¦çã§èªå°ããOct4-GFP+ç´°èã¯ï¼ã¤ã®èèã®èªå°ä½ãçãããFig. 2d, ED. 3dããããããããããããããããâ
ã»ãã¦ã¹ã«ç§»æ¤ããã¨ãä½pHå¦çã§èªå°ããOct4-GFP+ç´°èã®éå£ã¯å¥å½¢è
«ãå½¢æãã(40% n=20)ããOct4-GFP+ç´°èãæç¶çã«å«ã¾ããå¥å½¢çè
«ã¯çããªãã£ãã(n=50)
Fig. 2e, ED. 4a-c
ã»æ§ã
ãªOct4-GFPã®ã·ã°ãã«ã¬ãã«ã®ãã®ãããã®ã§ã7æ¥å¾ã«FACSã«ããå¼·GFPç´°èï¼ä¸»è¦éå£ï¼ã¨å¼±GFPç´°èï¼å°æ°éå£ï¼ã«åãã¦ãã¦ã¹ã«å
¥ããã¨ãå¼·GFPç´°èã¯å¥å½¢è
«ãå½¢æãããED. 4d
ã»å®éçPCR(qPCTR)解æã§ãå¼·GFPéå£ã¯å¤è½æ§ãã¼ã«ã¼éºä¼åãçºç¾ãããåæã®ç³»çµ±ç¹ç°çãªãã¼ã«ã¼éºä¼åãçºç¾ãã¦ããªãã£ããä¸æ¹ãå¼±GFPéå£ã¯ããã¤ãã®åæ系統ãã¼ã«ã¼éºä¼åãããªãçºç¾ãã¦ããããNanog㨠Rex1ã¯çºç¾ãã¦ããªãã£ãã
ED. 4e
ããããããããããããããããâ
ã»ãããã®è¦³å¯çµæã¯ãï¼ã¤ã®èèã®èªå°ä½ã¯ãå¼±GFPéå£ããã§ã¯ãªããå¤è½æ§ãã¼ã«ã¼éºä¼åãçºç¾ãã¦ããå¼·GFPéå£ããç£çããããã¨ã示ãã¦ããã
â»ä½ç´°èã®ååç¶æ
ã¯ãå¤é¨ããã®å¼·ãåºæ¿ãä¸ãããã¨ã§å¤è½æ§ã®ç¶æ
ã«å¤ããããã
ããããç¶æ
ã®å¤åããåºæ¿èªå°å¤è½æ§ç²å¾ã(STAP)ããã®çµæå¾ãããç´°èãSTAPç´°èã¨å¼ã¶ãã¨ã«ããã
ã»ç¢ºç«æ¡ä»¶ä¸ã§ã¯ãSTAPç´°èã¯ãã£ãã«å¢æ®ããªããED. 2d and 5a, b
ã»STAPç´°èã®æ¯è¼ã²ãã ãã¤ããªãã¤ã¼ã¼ã·ã§ã³ã¯ãæè²ä½æ°ã«ã¯å¤§ããªå¤åã¯ãªããã¨ã示ãããED. 5c
STAP cells compared to ES cells
ã»STAPç´°èã¯ããã¦ã¹ã®ESç´°èã¨ã¯éããLIFæ·»å å¹å°ã§ã®èªå·±è¤è£½è½åãéããã¦ãããåé¢ã«ããã¢ããã¼ã·ã¹ãæããROCKé»å®³å¤ã®Y-27632ãå
¥ã£ã¦ãã¦ããåé¢å¹é¤ããã¨ã³ããã¼ãå½¢æããå¹çãæªããFig. 2f, g / Fig. 2h
ã»é¨åçãªåé¢å¾ã«é«å¯åº¦å¹é¤ãã¦ããSTAPç´°èã®æ°ã¯ï¼åã®ç¶ä»£å¾ã«ã¯ããªãæ¸ãå§ãããFig. 2i
ã»STAPç´°èã§ã¯ãESãã¼ã«ã¼ã¿ã³ãã¯è³ªã§ããEsrrβã®çºç¾ãä½ããED. 5d, e
ã»ã¡ã¹ã®CDï¼ç´°èã¨EpiSCsã¨ç°ãªããä¸è¬çã«ã¡ã¹ã®ESç´°èã¯Xæè²ä½ã®ä¸æ´»æ§åã示ããH3K27me3é«å¯åº¦ç¹(ä¸æ´»æ§Xæè²ä½ã®ææ¨)ãæããªãã
ã»å¯¾ç §çã«ãå¼·Oct4-GFPçºç¾ã®ã¡ã¹ã®STAPç´°èã®40%ã«H3K27me3é«å¯åº¦ç¹ãè¦ããããED. 5f, g, h
ã»STAPç´°èã¯ãEpiSCsã¨ãä¼¼ã¦ããããKlf4ãã¸ãã£ãã§ä¸ç®å¯ççµåãã¼ã«ã¼ã®claudin 7 ã¨ZO-1ããã¬ãã£ãã§ãã£ãã
ED. 5d, e
STAP cells from other tissue sources
çå¾1é±éã®Oct4-gfpãã¦ã¹ã®è³ã»ç®èã»çèã»èèªã»éª¨é«ã»èºã»èèã®çµç¹ããéããä½ç´°èã§åæ§ãªè»¢æå®é¨ãè¡ã£ãã
ãããããããããããããâ
転æå¹çã¯æ§ã
ã§ãã£ãããFACSã§CD45ãã¬ãã£ãã«ã½ã¼ããããèèªã®éå
ç¹ç´°èãæ°çä»ã®å¿èç´°èãªã©ãå®é¨ããå
¨ã¦ã®çµç¹ã®å¹é¤ã§ä½pHåºæ¿ã§ç£çãããOct4-GFPï¼ç´°èã観å¯ããããNkx2-5ãå¿èã®ã¢ã¯ãã³ãªã©ã®éºä¼åã®çºç¾ã¯æãããã¦ãããã
Fig. 3a, ED. 6a-c / Fig. 3a-c / Fig. 3d-g, ED. 6d
Chimaera formation and germline transmission in mice
ã»GFPã常çºç¾ããæ°çä»ãã¦ã¹(cag-gfpå°å
¥éºä¼åãæã¤C57BL/6系統ï¼B6GFP)ã®CD45ï¼ç´°èããç£çããSTAPç´°èã®èç¤è注å
¥è©¦é¨ãè¡ã£ãã
ããããããããããããããâ
ã»STAPç´°èéå£ãã²ã¨ã¾ã¨ãã«ãã¦ããã¤ã¯ããã¤ãã使ã£ã¦æä½æ¥ã§å°çã«åã注å
¥ãããFig. 4aããããããããããããããâ
ã»GFPçºç¾ã®é«ããã®ããä¸ç¨åº¦ã®ç´°èããã¡ã©èã«è¦ãããããã¡ã©ãã¦ã¹ã¯é«é »åº¦ã§çã¾ããå
¨ã¦æ£å¸¸ã«çºçãããFig. 4b, ED. 7a / Fig. 4c, ED. 7bããããããããããããããâ
ã»CD45ï¼ç´°èç±æ¥ã®STAPç´°èã®å¯ä¸ãå
¨ã¦ã®çµç¹ã«å¯¾ãã¦èª¿ã¹ããããFig. 4d
ããããããããããããããâ
ã»STAPç´°èããä½æãããåå«ããã¡ã©ãã¦ã¹ããçã¾ãããããã¯ãéºä¼çã»å¾æçãªæ£å¸¸ãã¨åæ§ã«å¤è½æ§ã®å³ããå¤å®åºæºã§ããçæ®ç´°èç³»ä¼éã示ãã¦ããã
Fig. 4e, ED. 7c
ã»çºçè½åã®æãå³æ ¼ãªè©¦é¨ã§ããååä½èè£å®æ³ã§ãCD45ï¼ç´°èç±æ¥ã®STAPç´°è(B6GFPÃ129/Svã¾ãã¯DBA/2ãã)ã¯ãèçæ(E)10.5ã§å
¨ã¦ãGFPï¼ã®èå
ãä½ãåºãããããã¯ãSTAPç´°èåç¬ã§å
¨ã¦ã®èæ§é ãå½¢æã§ãããã¨ã示ãã¦ããã
Fig. 4f, ED. 7d
ãããããããããããããããâ
ã»STAPç´°èã¯çä½å
ã§çæ®ç´°èç³»ã¨åæ§ã«å
¨ã¦ã®ä½ç´°èç³»ã«ååããçºè²è½ãæã£ã¦ããã
â»ååä½èè£å®æ³ï¼tetraploid complementation assayï¼ï¼ããã©ããã¤ã(4åä½)ã®èã¯ãèä½å¤(èç¤ãªã©)ã«ã¯å¯ä¸ã§ããããèä½(èä»)ã«å¯ä¸ã§ããªããããã§ãå¤è½æ§å¹¹ç´°è(ESç´°èãiPSç´°è)ã¨4åä½èã®ãã¡ã©ãä½è£½ãããã¨ã§100%å¤è½æ§å¹¹ç´°èç´°èç±æ¥ã®èä»ãä½ãåºããã¨ãã§ããã
Expandable pluripotent cell lines from STAP cells
ã»STAPç´°èã¯ã確ç«ããã®ã«ä½¿ã£ãæ¡ä»¶ä¸ã§ã¯èªå·±è¤è£½è½åã«éçãããã
Fig. 2g, ED.2e, 5a
ã»STAPç´°èã¯ãèå
ã®ç°å¢ã§ã¯STAPç´°èéå£ã®å°ããªæçããèå
å
¨ã¦ã«æé·ãããã¨ãã§ãããFig. 4f
ãããããããããããããããâ
ã»STAPç´°èããç¹å®ã®æ¡ä»¶ä¸ã§ã¤ã³ãããã§å¢æ®å¯è½ãªå¤è½æ§ç´°èãä½ãè½åãããã調ã¹ããé常ã®LIF+FBSå«æå¹å°ã2iå¹å°(大åã®STAPç´°èã¯2iå¹å°ã§7æ¥å
ã«æ»ã¬)ã§ã¯å¹ççã«ç¶ä»£ãã¦ç¶æã§ããªããED. 8a
ãããããããããããããããâ
ã»ESç´°èã®ã¯ãã¼ã³å¢æ®ãä¿é²ãããã¨ãç¥ããã¦ããå¯è
ç®è³ªåºæ¿ãã«ã¢ã³(ACTH)+Lifå«æå¹å°(ACTHå¹å°)ããSTAPç´°èã³ããã¼ã®å¢æ®ãè£å©ãããMEFãã£ã¼ãã¼ãã¼ã©ãã³ä¸ã«ãã®å¹å°ã§å¹é¤ããã¨ãä¸é¨ã®STAPç´°èéå£ãæé·ãéå§ãã(96ã¦ã§ã«ãã¬ã¼ãã§1ã¦ã§ã«ã«ã¤ã1ã¤ã®ç´°èå¡ãã10ã20%ã12ç´°èå¡ã ã¨70%ããé«é »åº¦)ãFig. 5a
â»ãã£ã¼ãã¼ç´°èï¼å¢æ®ãååãèµ·ãããããã¨ããç®çã®ç´°èã®å¹é¤æ¡ä»¶ãæ´ããããã«ç¨ããï¼è£å©å½¹ãæããä»ã®ç´°è種ãé常ãã£ã¼ãã¼ç´°èã¯å¢æ®ããªãããã«ãããããã¬ã³ãç·ç §å°ãæçç©è³ªã«ãã£ã¦å¦çãã¦ãããMEF feederï¼èç·ç¶è½ç´°èï¼MEFï¼ããã¤ããã¤ã·ã³C çã§å¦çãããã¨ã«ããæ糸åè£çã«ä¸æ´»åãã¦ä½¿ç¨ã
ãããããããããããããããâ
ã»æé·ããã³ããã¼ã¯ãè¦ãç®ããã¦ã¹ESç´°èã¨ä¼¼ã¦ãããOct4-GFPã®çºç¾ãé«ãã£ãã
ãããããããããããããããâ
ã»ACTHå¹å°ã§7æ¥éå¹é¤ããå¾ãæé·ããç´°èã®éå£ã¯è¦ªSTAPç´°èã¨ã¯ä¼¼ã¦ããããåç¬ã®ç´°èã¨ãã¦å¹é¤ã§ãããFig. 5a, Fig. 5b
ãããããããããããããããâ
å°ãªãã¨ãå¹é¤120æ¥ã¾ã§2iå¹å°ã§è²ã¡ãææ°çã«å¢æ®ãã(æè²ä½ã®ç°å¸¸ã¯ã»ã¨ãã©ç¡ãã£ã)ãED. 8a / Fig. 5c, ED. 8b, cãããããããããããããããâ
ã»STAPç´°èããä½æããå¢æ®è½ãããç´°èãSTAP幹細èã¨åä»ããã
STAP幹細èã¯ãå¤è½æ§ç´°èã®ã¿ã³ãã¯è³ªã¨RNAã®ãã¼ã«ã¼ãçºç¾ãã¦ãããOct4ã¨Nanogã®å ´æã§ã¯ä½ãDNAã¡ãã«åã示ãããESç´°èã¨ããä¼¼ãæ ¸æ§é ãæã£ã¦ãã(é»åå¯åº¦ã®å°ãªãé åã¯ãããã¯ãããã³ã«å¯¾å¿ãã)ãFig. 5d, e / ED. 8d / ED. 8e
ãããããããããããããããâ
ååå¹é¤ã§ã¯ãSTAP幹細èã¯çä½å¤ã§ãé¼åããå¿çç´°èãå«ãå¤èèã»ä¸èèã»å
èèã®èªå°ä½ãç£çããçä½å
ã§å¥å½¢è
«ãå½¢æãã(å¥å½¢è
«çè
«ã®å½¢æã¯ãªã n=40)ã
Fig. 5f-h, ED. 8f, g / Fig.5i, ED. 8h
ãããããããããããããããâ
ã»èç¤èã«æ³¨å
¥å¾ãSTAP幹細èã¯å¹ççã«ãã¡ã©ãã¦ã¹ãä½ããçæ®ç´°èä¼éãè¦ãããã
Fig. 5j / ED. 8i â
ã»ååä½èè£å®æ³è©¦é¨ã§ãã注å
¥ããSTAP幹細èã¯æä½ã«æé·ã§ãããã¦ã¹ãä½ããã¨ãã§ããåå«ãçã¾ãã(8ã¤ã®ç¬ç«ãã系統å
¨ã¦)ãFig. 5k, l, ED. 8j
â
ã»å¢æ®è½åã«å ãã¦ãSTAP幹細èã¨è¦ªSTAPç´°èã«ã¯2ã¤ã®éããããã1ã¤ã¯STAPç´°èã§ã¯æ¤åºã§ããªãESç´°èãã¼ã«ã¼ã¿ã³ãã¯è³ªã®Esrrβã®çºç¾ãã¯ã£ããã¨ãããã¨ãããï¼ã¤ã¯ãã¡ã¹ã®STAPç´°èã§ã¯ããªãè¦ãããH3K27me3éä¸ç¹ã®åå¨ããSTAP幹細èã§ã¯è¦ãããªããã¨ãED. 5d, e / Fig. 5e / ED. 5f, 8kãããããããããããããããâ
ã»STAP幹細èã¯ãå¢æ®è½åã®ããç´°è系統ãä½ãããã¨çãESç´°èã¨ä¼¼ã¦ããã
Discussion
ã»ãã®è«æã¯ãä½ç´°èãæ½å¨çã«é©ãã¹ãæè»æ§ãæã£ã¦ãããã¨ãæããã¦ãããé常ã®ç°å¢ã§ã¯çµé¨ãããã¨ã®ãªãä¸æçãªå¼·ãåºæ¿ã«æããããã¨ã§ãå¤è½æ§ç´°èã«ãªããã¨ãããã¤ãããã¯ãªæè»æ§ãæããã«ãªã£ãã
ã»ä½pHå¦çã¯ã1947å¹´ã«Holtfreterã«ãããèªå·±ç¥çµç§ãå®é¨ã§ãç¨ãããããããã¯ãçä½å¤ã§ããµã³ã·ã§ã¦ã¦ãªã®åç©æ¥µãé ¸æ§å¹å°ã«æãã¨Spemannã®ãªã¼ã¬ãã¤ã¶ã¼ã·ã°ãã«ãç¡ãã¦ãçµç¹èªå¾çãªç¥çµè»¢æãèµ·ããã¨ãããã®ã§ãããã¡ã«ããºã ã¯åãã£ã¦ããªãããHoltfreterã¯å¼·ãåºæ¿ãåç©æ¥µã®ç´°èã®éå½è»¢æãæå¶ãã¦ããä½ããã®å å çãªé»å®³ã¡ã«ããºã ã解æ¾ããã¨æ¨æ¸¬ãããå½¼ã®è¨èã§ããã¨ãäºè´æ»æ§ã®ç´°è溶解ã(ç´°èã®é»å®³ç¶æ ã解ãåºæ¿èªèµ·ãæå³ãã)ãééãããã¨ã
ã»Holtfreterã®ç 究ãä»ã®ç°ãªã£ãæ¹åã§ã®éå½è»¢æâç´ç«æ©è¡ã®ååã¨æ ¸ã®ãªããã°ã©ãã³ã°âã®ç¾è±¡ã¯ãç¹ã«äºè´æ»æ§ã®åºæ¿èªçºã«ããç´°èã®åºå® (転ææµæ) çãªç¶æ ãã解æ¾ããå¹¾ã¤ãã®å ±éããé¢ããããããããªãã
ã»æ®ãããçåã¯ãç´°èã®ãªããã°ã©ãã³ã°ãä½pHå¦çã§ç¹å¥ã«åæåãããã®ããç©ççãã¡ã¼ã¸ã»ç´°èèã®ç©¿åå¦çã»æµ¸éå§ã·ã§ãã¯ã»æé·å åã®æ¬ å¦ã»ç±ã·ã§ãã¯ã»é«Ca2ï¼æé²ãªã©ã®å¹¾ã¤ãã®ä»ã®ã¿ã¤ãã®äºè´æ»æ§ã¹ãã¬ã¹ã§ãèµ·ããã®ãã¨ãããã¨ã§ããã
ã»å°ãªãã¨ãããããã®ã¹ãã¬ã¹ã®å¹¾ã¤ããç¹ã«ãã¤ãæ©ç ã¨ã¹ãã¬ãããªã·ã³Oã«ããç´°èèã®ç©¿åå¦çã«ããç©ççãã¡ã¼ã¸ã¯ãCD45ï¼ç´°èããOct4-GFPï¼ã®ç£çãèªå°ããã
ED. 9a
ã»ãããã®ç¥è¦ã¯ãããå ±éãã調ç¯ã¢ã¸ã¥ã¼ã«ããããã®é ãé¢ä¿ã®äºè´æ»æ§ã¹ãã¬ã¹ã®ä¸æµã«ãããä½ç´°èã®ååãå¼·åºã«åºå®ããå¾æçãªç¶æ ãã解æ¾ãã¦å¾æçãªå¶å¾¡ã«å¤§å±çãªå¤åãããããéµã¨ãã¦åãã¦ããå¯è½æ§ãæµ®ãã³ä¸ãããããè¨ãæããã¨ãäºè´æ»æ§ã®åºæ¿ã§æ´»æ§åããæªç¥ã®ç´°èæ©è½ããä½ç´°èãç¾å¨ã®ææãã解æ¾ãã¦æªååç´°èã®ç¶æ ã«æ»ãã¦ãããããããªãã
ã»ææãããä½ç´°èã§ã®å¾¹åºçãªãªããã°ã©ãã³ã°ã¨ããäºæ³å¤ã®å¤§ããªè½åã¯ãæ§ã ãªéè¦ãªåããæµ®ãã³ä¸ãããããä¾ãã°ãã©ããã¦ãã¾ãã¯ä½ã®ããã«ãä½ç´°èã¯äºè´æ»æ§åºæ¿ã®å¾ã ãã«ç¾ãããªããã°ã©ãã³ã°ããèªå·±éç¨è½åãæ½å¨çã«æã£ã¦ããã®ããã©ããã¦ããã®ãªããã°ã©ãã³ã°ã¡ã«ããºã ãé常ã¯æå¶ããã¦ããã®ããããã«ãã©ããã¦å¼·ãç°å¢ã¹ãã¬ã¹ãåããå¯è½æ§ã®ããã¤ã³ããã®çµç¹ã§å¥å½¢è «(ã¾ãã¯å¤è½æ§ç´°èè «ç¤)ã®å½¢æãæ®éã«è¦ãããªãã®ãã
ã»æã ã®äºåçãªç 究ã§ã¯ãéæµæ§é£éçãå±æçã«Oct4-GFPã®ä¸ç¨åº¦ã®çºç¾ãèªå°ããããå å¨æ§ã®Nanogã¯ãã¦ã¹ã®é£éç²èã«çºç¾ãã¦ããªããä»å¾ã®ç 究ã«ã¤ãã¦ã®èå³æ·±ã仮説ã¯ãæåã®Oct4æ´»æ§åãããªããã°ã©ãã³ã°ã®éç¨ãã¤ã³ããã§ã¯ããé»å®³ã¡ã«ããºã ã«ãã£ã¦æå¶ããã¦ããã¨ãããã®ã§ãããED. 9b
ã»ãªããã©ããã¦ããã®èªå·±éç¨ãªããã°ã©ãã³ã°ãå¤è½æ§ç¶æ ã«åããã®ãã¨ããã®ã¯åºæ¬çã«éè¦ã§ãããSTAPãªããã°ã©ãã³ã°ã¯å¤è½æ§ãã¼ã«ã¼éºä¼åãããªãçºç¾ããã¾ã§ã«ãã£ãæ°æ¥éã¨ãã極ãã¦çæéã§ãããéºä¼åå°å ¥ãåå¦çãªèªå°ã«ããiPSç´°è転æã¨ã¯ç°ãªã£ã¦ãããæã ã®çµæã¯ãå¤ç´°èçç©ã§ã®å¤æ§ãªç´°èç¶æ ã®çç©å¦çãªæå³ã«æ°ããå ãæãããããã®ã§ããã
METHODS SUMMARY
çµç¹æ¡éã¨ä½pHæé²
çå¾1é±éã®Oct4-gfp C57BL/6ãã¦ã¹ããè¾èãåé¤
ããããâ
ããµãã§ç´°ããåãããã¹ãã¼ã«ããããã§æ©æ¢°çã«åé¢
ããããâ
åé¢ããç´°èãéããDMEMå¹å°ã«åæ¸æ¿ããåéã®lympholyte (Cedarlane)ãå ãã
ããããâ
1,000gã§20åé å¿
ããããâ
CD45ãã¸ãã£ãç´°èãFACS Aria (BD Biosciences)ã§é¸å¥
ããããâ
ä½pHã®HBSS溶液(pH5.7ã37 âã§25åé)
ããããâ
5åéé å¿ãã¦ä¸æ¸
ãæ¨ã¦ã
ããããâ
1,000U LIF (Sigma) ã¨B27 (Invitrogen)ãæ·»å ããDMEM/F12å¹å°ã®å
¥ã£ãéæ¥çå¹é¤ãã¬ã¼ãã«èã
Oct4-GFPï¼ç´°è(å¤è½æ§é¢é£ã¿ã³ãã¯è³ªã¨éºä¼åãã¼ã«ã¼ã®çºç¾ã¨ã3èèèªå°ä½ã¸ã®ååè½ãæã¤)ã¯ãè¥ããã¦ã¹(ä¾ãã°çå¾6é±é)ã®ãªã³ãçãããåãå¹é¤æ¡ä»¶ä¸ã§ä½ãããããããã®å¹é¤ä¸ã§ã®å²åã¯ãæ°çä»ã®ãªã³ãç(çå¾1é±éããããããåé¢)ã¨æ¯ã¹ãã¨æ°åãã10åå°ãªãã
ã©ã¤ãã¤ã¡ã¼ã¸ã³ã°ã¯ãCO2ã¤ã³ãã¥ãã¼ã¿ã¼ãç¹å¥ã«çµã¿è¾¼ãã å ±ç¦ç¹é¡å¾®é¡ãç¨ãã¦è¡ããçç´°èã®CD45å ç«æ´»æ§ã¯è¿°ã¹ãæ§ã«ãã¦èª¿ã¹ãã
çä½å ã¨çä½å¤ã§ã®åå試é¨
ï¼»çä½å
ï¼½
STAPç´°èãããªã°ã«ã³ã¼ã«é
¸ç¹ç¶ããæãä¸ç¹å¸3Ã3Ã1 mmã®ã·ã¼ãã«èã
ããããâ
çå¾4é±éã®NOD/SCIDãã¦ã¹ã®èå´ã®ç®ä¸ã«ç§»æ¤
ï¼»çä½å¤ï¼½
STAPç´°èã¨STAP幹細èãå¹é¤7æ¥å¾ã«éãã
ããããâ
ç¥çµã¸ã®ååï¼SDIAã¾ãã¯r SFEBqå¹é¤
ä¸èèã¨å
èèã¸ã®ååï¼èèä½å¹é¤
METHODS
åç©è©¦é¨
åç©ãå«ãç 究ã¯ãHarvard Medical School/Brighamã»Womenâs Hospital Committee on Animal Careã»Institutional Committee of Laboratory Animal Experimentation of the RIKEN Center for Developmental Biologyã«ãã£ã¦æ¿èªããã¦ãããããã³ã¼ã«ã«å¾ã£ãã
çµç¹æ¡éã¨ä½pHæé²
ï¼»CD45ï¼é è¡ç´°èã®åé¢ï¼½
çå¾1é±éã®Oct4-gfp C57BL/6ãã¦ã¹(ç¹ã«æè¨ããªãéã)ããè¾èãåé¤
ããããâ
ããµãã§ç´°ããåãããã¹ãã¼ã«ããããã§æ©æ¢°çã«åé¢
ããããâ
åé¢ããç´°èãPBSã«åæ¸æ¿ããcell strainer (BD Biosciences)ãéãã¦æ¿¾ã
ããããâ
1,000 r.p.m. ã§5åéé å¿
ããããâ
éããç´°èãDMEMå¹å°ã«åæ¸æ¿
ããããâ
åéã®lympholyte (Cedarlane)ãå ãã
ããããâ
1,000gã§20åé å¿
ããããâ
ãªã³ãç層ãåãåºããCD45 antibody (ab25603, Abcam)ã§æè²
ããããâ
CD45ãã¸ãã£ãç´°èãFACS Aria (BD Biosciences)ã§é¸å¥
ããããâ
1Ã10^6åCD45ãã¸ãã£ãç´°èã500μlã®ä½pHã®HBSS溶液(HClã§pH5.7ã«èª¿æ´)ã§37 âã»25åéå¦ç
ããããâ
室温ã«ã¦1,000 r.p.m.ã§5åéé å¿ãã¦ä¸æ¸
(ä½pH溶液)ãæ¨ã¦ã
ããããâ
æ²æ®¿ããç´°èã1,000U LIF (Sigma) ã¨2% B27 (Invitrogen)ãæ·»å ããDMEM/F12å¹å°ã§åæ¸æ¿ãããã®å¹å°ã®å
¥ã£ãéæ¥çå¹é¤ãã¬ã¼ãã«èã(ä¸è¬çã«1Ã10^5 ç´°è/ml)
[ç´°èå¡ã®å½¢æ]
ã»Oct4-GFPï¼ç´°èã®å²åããããæ¤ããç´°èã®å¯åº¦ã®æ¹ã«å½±é¿ãåããã
ã»çåç´°èã®æ°ã¯ãæä¾ãããã¦ã¹ã®å¹´é½¢ã®å½±é¿ãåãã大人ã®ãã¦ã¹ã®è¾èãç¨ããå¦çæ¡ä»¶ã§ã¯ä½ããªã£ãã
ã»å¹é¤7æ¥å¾ã®Oct4-GFPï¼ STAPç´°èå¡ã®ç£çã«ã¯ãå¹é¤2æ¥ã7æ¥ã®éã«LIFã®æ·»å ãå¿
é ãED. 1f
ã»LIFãç¡ãã¦ããä½pHå¦çããCD45ï¼ç´°èãå¹é¤ãã¦2ã5æ¥å¾ã®éã«Oct4-GFPï¼ç´°è(ãã®ã»ã¨ãã©ã¯å¼±ãã·ã°ãã«)ãä¸æçã«ç¾ãããããã®å¾æ¶ãããLIFã«ä¾åããªãåæã®æ®µéãããããããã«ç¶ã段éã«ã¯LIFä¾åçã§ãããã¨ã示ãã¦ããã
ãã¡ã©ãã¦ã¹ã®ä½æã¨è§£æ
[STAPç´°èã使ã£ã2åä½ã¨4åä½ãã¡ã©ã®ä½æ]
ã»2åä½ã®èï¼ICR 系統ã®ã¡ã¹ããå¾ã
ã»4åä½ã®èï¼2ç´°èèãé»æ°èåãã¦ä½æ
æä¾ãµã³ãã«ã®ããªãã·ã³å¦çã¯ãã¡ã©åãä½ããªããã¨ãå¤æã
STAPçç¶ã³ããã¼ãé¡å¾®é¡ä¸ã§ãã¤ã¯ããã¤ãã使ã£ã¦å°ããåã
ããããâ
STAPç´°èã®å°ããªå¡ãã大ããªããããã§4.5æ¥ã®èç¤èã«æ³¨å
¥
ããããâ
ç¿æ¥ããã¡ã©èç¤èã2.5æ¥ã®å½å¦å¨ ãããã¡ã¹ã«ç§»æ¤
ã»Oct4-gfp ã¬ãã¼ã¿ã¼ã§ã¯ãªãCD45ï¼ç´°èããã®STAPç´°èã使ã£ãå®é¨ã§ã¯ãSTAPç´°èå¡ã¯ãã®ç¹å¾´çãªå¡ã®å½¢æ ã§å¤å¥ããã(ã¨ã¦ãå°ããç´°èããæããåéã«å¼·ãå§ç¸®ã¯ã¯ãªã)
STAP転ææ¡ä»¶(ä½pH)ãCD45ï¼ãªã³ãçã«é©ç¨ããã¨ã7æ¥å¾ã®å¡ã®å¤ãã¯å¤§ãããªããæ°åå以ä¸ã®å°ããªç´°èãå«ã¾ãã¦ãããOct4ãã¸ãã£ã(çºç¾ã¬ãã«ã¯æ§ã
)ã«ãªã
ããããâ
ç¹å¾´çãªå¡ãããå½¢æ(大ãã)ããããã®ã ãããã®ã¿ã¤ãã®å®é¨ã«ä½¿ç¨
ããããâ
ãã¤ã¯ããã¤ãã§åæããã¬ã©ã¹é注å
¥ã«é©å½ãªå¤§ããã«ãã¦æä¾ç´°èå¡ã調æ´
[注å
¥ããç´°èã®å¯ä¸ã®æ¨å®]
GFPã常çºç¾ãããã¦ã¹(cag-gfp å°å
¥éºä¼åãæã¤C57BL/6系統ï¼é種強å¢ã®è¦³ç¹ããC57BL/6ã¨129/Svã¾ã㯠DBA/2ã®F1)ã®CD45ï¼ç´°èããä½æããSTAPç´°èã使ç¨
ããããâ
æ°çä»ã®è¾èããå¾ãããCD45ï¼ç´°èæ°ãå°ãªãã£ãã®ã§ãSTAPç´°è転æã«ãªã¹ã¨ã¡ã¹ã®ãã¦ã¹ã®è¾èç´°èãæ··ãã
ã»çæ®ç³»åä¼éãããå¹ççã«ãããããããã¤ãã®å®é¨ã§ã¯ãã¡ã©ã交é
[STAP幹細èã使ã£ã2åä½ã¨4åä½ãã¡ã©ã®ä½æ]
ã»2åä½ã®èï¼ICR 系統ã®ã¡ã¹ããå¾ã
ã»4åä½ã®èï¼2ç´°èèãé»æ°èåãã¦ä½æ
STAP幹細èãï¼ã¤1ã¤ã®ç´°èã«åé¢
ããããâ
4.5æ¥ã®èç¤èã«æ³¨å
¥
ã»STAPç´°èã¨STAP幹細èã®ãã¡ã©ã調ã¹ããããã®ãã¡ã©ãåå«ã«ã¯è «çåããå¾åã¯è¦ãããªãã£ãã
çä½å
åå試é¨
[STAPç´°è]
1Ã10^7 åã®STAPç´°èãããªã°ã«ã³ã¼ã«é
¸ç¹ç¶ããæãä¸ç¹å¸ã®ã·ã¼ã(3Ã3Ã1 mmï¼ç©´å¾ã¯200 μm)ã«èã
ããããâ
DMEMï¼10% FBSå¹å°ã§24æéå¹é¤
ããããâ
çå¾4é±éã®ãã¦ã¹ã®èå´è
¹é¨ã®ç®ä¸ã«ç§»æ¤
ããããâ
å±æçã«å¯éããç¶æ
ã«ä¿ã¤ãã¨ã§ããã£ããããSTAPç´°èã®æé·ããè
«çã®å½¢æãè£å©ããçºãããªã°ã«ã³ã¼ã«é
¸ç¹ç¶ã§ä½ããã人工çãªè¶³å ´ã¨ä¸ç·ã«STAPç´°èã移æ¤
ããããâ
ææã®äººå·¥çãªæ§è³ªã«ãããå質éºä¼çãªãã¦ã¹ã§ããã®è¶³å ´ã«ãã移æ¤å¾ã«ççãèµ·ããã®ã§ããããåé¿ããããã«NOD/SCIDãã¦ã¹ã宿主ã¨ãã¦ä½¿ç¨
[STAP幹細è]
STAP幹細èã1ã¤1ã¤ã®ç´°èã«åé¢
ããããâ
1Ã10^7åãå«ãç´°èæ¸æ¿æ¶²ã精巣ã«æ³¨å
¥
ããããâ
6é±éå¾ã移æ¤ç©ãçµç¹åå¦çãªæè¡ã«ãã解æ
[観å¯æ¹æ³]
移æ¤ç©ã10%ãã«ã ã¢ã«ãããã§åºå®ãããã©ãã£ã³ã«å
åãã¦4μmã®åã¿ã®åçã«ãã
ããããâ
ã»åçãããããã·ãªã³ã»ã¨ãªã·ã³æè²
ã»å
èèçµç¹ï¼æα-fetoprotein(ãã¦ã¹ã¢ãã¯ãã¼ãã«æä½; MAB1368, R&D Systems)
ã»å¤èèçµç¹ï¼æ -βIII tubulin (ãã¦ã¹ã¢ãã¯ãã¼ãã«æä½; G7121, Promega)
ã»ä¸èèçµç¹ï¼æ -α-smooth muscle actin (ã¦ãµã®ããªã¯ãã¼ãã«æä½; DAKO)
ã»ãã¬ãã£ãã³ã³ããã¼ã«ï¼ä¸æ¬¡æä½ãåãã¢ã¤ã½ã¿ã¤ãã®IgGæä½ã«ãã
ä»ã®å¤é¨åºæ¿ã®æé²ã«ããSTAP
[æ©æ¢°çãªã¹ãã¬ã¹]
ãã¹ãã¼ã«ãããããå ç±ãã¦ä¼¸ã°ããå
å¾ç´50μmã®ç´°ããã£ãã©ãªã¼ã«ãã
ããâ
é©å½ãªé·ãã«æã
ããâ
æçããä½ç´°èããããã®ãããããéãã¦20åéç¹°ãè¿ãã¦æ©ç ãã
ããâ
7æ¥éå¹é¤
[ç±ã·ã§ãã¯]
ç´°èã42âã§20åéç±ãä¸ãã
ããâ
7æ¥éå¹é¤
[æ é¤æ¬ ä¹]
ç´°èãåºæ¬å¹å°ã§3é±éå¹é¤
[é«Ca2ï¼æ¿åº¦]
2mM CaCl2ãå«ãå¹å°ã§7æ¥éå¹é¤
[ç´°èèã«ç©´ãéãã]
ç´°èã230 ng /mlã® streptolysine O(SLO) (S5265, Sigma)ã§2æéå¦ç
ããâ
7æ¥éå¹é¤
åå¦çã®å¾ãOct4-GFPãã¸ãã£ãç´°èã®æ¯çãFACSã§è§£æ
Bisulphiteã·ã¼ã±ã³ã¹
STAPå¡ä¸ã®GFPãã¸ãã£ãç´°èãFACS Ariaã§éãã
ãããããâ
ã²ãã DNAãSTAPç´°èããæ½åº
ãããããâ
ãã¤ãµã«ãã¡ã¤ãå¦çãCpGenome DNA modification kit (Chemicon, http://www.chemicon.com) ãç¨ãã¦è¡ã
ãããããâ
å¾ããã修飾DNAã2ã¤ã®ãã©ã¯ã¼ã(F)ãã©ã¤ãã¼ã¨1ã¤ã®ãªãã¼ã¹ãã©ã¤ãã¼ã使ãnested PCRã§å¢å¹
ãPCRã¯TaKaKa Ex Taq Hot Start Version (RR030A)ãç¨ãã
[Oct4]
F1ï¼5'-GTTGTTTTGTTTTGGTTTTGGATA T-3'
F2ï¼5'-ATGGGTTGAAATATTGGGTTTATTTA-3'
Rï¼ 5'-CCACCCTCT AACCTTAACCTCTAAC-3'
[Nanog]
F1ï¼5'-GAGGATGTTTTTTAAGTTTTTTTT-3
F2ï¼5'-ATGGGTTGAAATATTGGGTTTATTTA-3'
Rï¼ 5'-CCACCCTCT AACCTTAACCTCTAAC-3'
ãããããâ
DNAã·ã¼ã±ã³ã¹ã¯M13 primerãç¨ãã¦Genome Resource and Analysis Unit, RIKEN CDBã§è¡ã
å ç«çµç¹åå¦çæ¤æ»
å¹é¤ããç´°èã4%ãã©ãã«ã ã¢ã«ãããã§åºå®
ããããâ
1% BSA solution ã§ããããã³ã°ããåã«ã0.1% Triton X-100/PBSã§éæå
ããããâ
次ã®ä¸æ¬¡æä½ã¨ä¸æ©ã¤ã³ãã¥ãã¼ããã
anti-Oct4 (Santa Cruz Biotechnology; C-10)
anti-Nanog (eBioscience; MLC-51)
anti-SSEA-1 (Millipore; MC480)
anti-E-cadherin (Abcam)
anti-ZO-1 (Santa Cruz Biotechnology; c1607)
anti-claudin7 (Abcam)
anti-Klf4 (R&DSystems)
anti-Esrrb (R&D Systems)
anti-H3K27me3 (Millipore)
anti-BrdU (BD Bioscience)
anti-Ki67 (BDPharmingen)
ããããâ
次ã®äºæ¬¡æä½ã¨ã¤ã³ãã¥ãã¼ã
Alexa-488 ã¾ãã¯Alexa -594ãçµåãã
goat anti-mouseã»goat anti-rabbit (Invitrogen)
ããããâ
ç´°èæ ¸ã¯DAPIã§å¯è¦å
ããããâ
ã¹ã©ã¤ãã«SlowFade Gold antifade reagent (Invitrogen)ãå ãã¦åãä»ãã
èå æ´»æ§åç´°èã®åé¢ã¨ããã¼ãµã¤ãã¡ããªã¼
ç´°èã¯æ¨æºçãªãããã³ã¼ã«ã«å¾ã£ã¦æºåããFACSã®åã«æ°·ä¸ã§0.1% BSA/PBSã«æ¸æ¿
ããããããâ
æ»ç´°èãé¤ãã®ã«Propidiumiodide (BD Biosciences)ãç¨ãã
ããããããâ
ç¹ç°æ§ã確ä¿ããããããã¬ãã£ãã³ã³ããã¼ã«ã¨ãã¦ãä¸æ¬¡æä½ã®ä»£ããã«åãã¢ã¤ã½ã¿ã¤ãã®IgGãã¬ãã£ãã³ã³ããã¼ã«ã使ã
ããããããâ
ç´°èãBD FACS Aria SORPã§åé¢
ããããããâ
BD LSRII with BD FACS Diva Software (BD Biosciences)ã§è§£æ
é è¡æ§ãã©ã¯ã·ã§ã³åé¢ã«ã¯ãTç´°èãã¼ã«ã¼(anti-CD90; eBioscience)ã¨é è¡åé§ç´°èãã¼ã«ã¼ (anti-CD34; Abcam)ãç¨ãã
RNA調æ´ã¨RT-PCR解æ
RNAã¯RNeasy Micro kit (Qiagen)ã§åé¢
ãããããâ
é転åãSuper Script III first strand synthesis kit (Invitrogen)ã§è¡ã
ãããããâ
Power SYBR Green Mix (Roche Diagnostics)ã使ç¨ããLightcycler-II Instrument (Roche Diagnostics)ã§å¢å¹
ã»åéºä¼åã®ãã©ã¤ãã¼ã»ããã¯ãSupplementary Table 1ã«ãªã¹ã
çä½å¤åå試é¨
[ä¸èèåå試é¨]
STAPç´°èã7æ¥å¾ã«éãã
ããããâ
Oct4-GFPãã¸ãã£ãç´°èãã»ã«ã½ã¼ã¿ã¼ã§åé¢
ããããâ
20% FBSãå ããDMEMå¹å°ã§å¹é¤ã3æ¥æ¯ã«å¹å°ã交æ
ããããâ
7ã14æ¥å¾ãçç´°èãæα-smooth muscle actinæä½ (DAKO)ã§æè²
[ç¥çµç³»çµ±åå試é¨]
STAPç´°èã7æ¥å¾ã«éãã
ããããâ
SDIAã¾ã㯠SFEBqå¹é¤
ã»SDIAå¹é¤ï¼éããSTAPç´°èå¡ãPA6æ¯æç´°èã®ä¸ã«èã
ã»SFEBqå¹é¤ï¼STAPç´°èå¡ã96ã¦ã§ã«ãã¬ã¼ãã«èã(ã¦ã§ã«æ¯ã«ï¼ã¤ï¼non-cell-adhesive 96-well plate, PrimeSurface V-bottom, SumitomoBakelite)ãæ¸æ¿æ¶²ãå¹é¤
[å
èèåå試é¨]
STAPç´°èã7æ¥å¾ã«éãã
ããããâ
96ã¦ã§ã«ãã¬ã¼ãã§æ¸æ¿æ¶²ãèªå°ç©è³ªã¨å¹é¤
TCR-βééºä¼ååç·¨æ試é¨
ã²ãã DNAãSTAPç´°èã¨ãCD45ï¼ç´°èç±æ¥ã®STAPç´°èããä½ã£ããã¡ã©ãã¦ã¹ã®å°¾ã®å
端ããæ½åº
ããããâ
DNA50ngã使ãã次ã®ãã©ã¤ãã¼ãç¨ãã¦(D)J åç·¨æé åãPCR
Dβ2ï¼5'-GCACCTGTGGGGAAGAAACT-3'
Jβ2.6ï¼5'-TGAGAGCTGTCTCCTACTATCGATT-3'
ããããâ
PCRç£ç©ã1.6% agaroseã§Tris-acetate-EDTA bufferã§ã²ã«é»æ°æ³³åããethidium bromideã§æè²
ããããâ
STAP ç´°èããã®PCRãã³ããã·ã¼ã±ã³ã¹ãã¦è§£æ
(D)J åç·¨æã«ãããåç·¨æããã²ãã æçãåå®
EdUåãè¾¼ã¿è©¦é¨ã¨ã¢ããã¼ã·ã¹è§£æ
[EdUåãè¾¼ã¿è©¦é¨]
Click-iT EdU Flow cytometry assay kit (Invitrogen)ã®ãããã³ã¼ã«ã«å¾ã£ã¦è¡ã
STAPç´°èå¹é¤ã®æ§ã
ãªæ®µé(0–2æ¥, 2–7æ¥, 7–14æ¥)ã§EdUãå¹å°ã«æ·»å
(æçµæ¿åº¦ï¼10 μM)
ããããâ
EdUã®åãè¾¼ã¿ãFACSã§è§£æ
[ã¢ããã¼ã·ã¹è§£æ]
Annexin-V (Biovision)ã¨propidium iodideãç¨ãã¦ããã¼ãµã¤ãã¡ããªã¼ã§è¡ã
14æ¥å¾ã§ã®FACSã«ããAnnexin-V解æã«ããã大åã®Oct4-GFPï¼ç´°èããã®ã¢ããã¼ã·ã¹ãã¼ã«ã¼é½æ§ã§ãããã¨ã示ãããããã®å¾ãçç´°èæ°ãæ¸å°ãã
è»å¯å¤©è©¦é¨
åé¢ããSTAPç´°è(Oct4-GFPå¼·ã¾ãã¯å¼±)ã¨ã³ã³ããã¼ã«ã®ãã¦ã¹ESç´°è(96ã¦ã§ã«ãã¬ã¼ãï¼1,000 ç´°è/ã¦ã§ã«)ãLIF-B27è»å¯å¤©å¹å°(0.4%ã¢ã¬ãã¼ã¹)ã«èã
ããããâ
å¹é¤7æ¥å¾ãç´°èãåé¢ããè¶³å ´éä¾åçæé·ãcytoselect 96-well cell transformation assay kit (Cell Biolabs)ãç¨ãã¦èå
è¨æ¸¬ã«ããå®é
æ¯è¼ã²ãã ãã¤ããªãã¤ã¼ã¼ã·ã§ã³(CGH)ã¢ã¬ã¤è§£æ
ã²ãã DNAãSTAP (ãªã¹) ã¨CD45é½æ§ç´°è (ãªã¹)ããGene JET Genomic DNA purification kit (Thermo Scientific)ãç¨ãã¦æ½åº
ããããâ
STAPç±æ¥ã®æè²ä½ã®æ£å¸¸æ§ã¯ãCGH array (Agilent)ãç¨ãã¦å¥ã®å®é¨ã§æè²ä½ã®æ£å¸¸æ§ã確ããããã¦ããCD45é½æ§ç´°èã¨æ¯è¼
ããããâ
CGHã¢ã¬ã¤ã¨ãã¼ã¿è§£æã¯TAKARA Bioã§å®æ½
é»åé¡å¾®é¡
åé¢ããç´°èãã0.1M cacodylate buffer (pH 7.2) ä¸ã§2.5%ã°ã«ã¿ã«ã¢ã«ãããã¨2%ãã«ã ã¢ã«ãããã§åºå®
ããããâ
èçãä½ãééé»åé¡å¾®é¡ã§è¦³å¯
çç´°èã¤ã¡ã¼ã¸ã³ã°
å
¨ã¦ã®çç´°èã¤ã¡ã¼ã¸ã³ã°ã¯ãLCV110-CSUW1 (Olympus)ã§è¡ã
ãããâ
CD45æä½æè²ã¯ãä½pHã§å¦çããCD45ï¼ç´°èã20 ng/mlã®èå
ã©ãã«CD45æä½(eBioscience)ãå«ãå¹å°ã«èãã¦è¡ã
RNAã·ã¼ã±ã³ã¹ã¨ChIPã·ã¼ã±ã³ã¹è§£æ
[RNAã·ã¼ã±ã³ã¹è§£æ]
å
¨RNAãRNasy mini kit (Qiagen)ãç¨ãã¦ç´°èããæ½åº
ãããããâ
RNA-seqã©ã¤ãã©ãªã¯ãTruSeq RNA Sample Prep kit (Illumina) ã®ãããã³ã¼ã«ã«å¾ã1μg ã®å
¨RNAãã調æ´
ãããããâ
Illumina Hi-Seq1500ã§å¤§è¦æ¨¡ã·ã¼ã¯ã¨ã³ã·ã³ã°
ãããããâ
æ§ã
ãªç´°èã¿ã¤ãã®éå£æ¨¹å½¢å³ãå
æ¬çãªçºç¾ãããã¡ã¤ã«(log2 FPKM of all transcripts; FPKM, fragments per kilobase of transcript per million mapped reads)ã®é層ã¯ã©ã¹ã¿ãªã³ã°ããå¾ã
ãããããâ
å®å
¨é£çµæ³ã1âr (r=ãããã¡ã¤ã«éã®ãã¢ã½ã³ç¸é¢)ã«é©ç¨ãããã®ã樹形å³ä½æã«ç¨ãã
ãããããâ
ãã¼ã»ã³ãåä½ã§çµ±è¨çã«ä¿¡é ¼ã§ããã¹ã³ã¢ãå¾ãã®ã«ããã¼ãã¹ãã©ããåãµã³ããªã³ã°ã®1000ãµã¤ã¯ã«ãè¡ã(AUP valuesã¨ãå¼ã°ãã)
[ChIPã·ã¼ã±ã³ã¹è§£æ]
ChIP-seqã©ã¤ãã©ãªã¼ã¯20 ngã®ã¤ã³ãããDNAã»1 ngã®H3K4me3 ChIP DNAã¾ã㯠5 ngã®H3K27me3 ChIP DNAsããKAPA Library Preparation kit (KAPA Biosystems)ãç¨ãã¦èª¿æ´
ãããããâ
TruSeqã¢ããã¿ã¼ã¯TruSeqã¦ããã¼ãµã«ãªãªã´ãã¯ã¬ãªããã¨åã¤ã³ããã¯ã¹ãªãªã´ãã¯ã¬ãªããã®ã¢ãã¼ãªã³ã°ã«ãã£ã¦å®¤å
ã§èª¿æ´
5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3'
5'-GATCGGAAGAGCACACGTCTGAACTCCAGTCACXXXXXXATCTCGTATGCCGTCTTCTGCTTG-3 (Xã¯ã¤ã³ããã¯ã¹ã·ã¼ã±ã³ã¹ã示ã)
ãããããâ
ã¯ãããã³å
ç«æ²éã¯ãç´°èã1%ãã«ã ã¢ã«ããããå«ãPBS(-)ã§å®¤æ¸©ã«ã¦10åéåºå®
ãããããâ
ã°ãªã·ã³ãæçµæ¿åº¦0.25Mæ·»å ããåºå®åæ¢
ãããããâ
氷温ã®PBS(-)ã§2åæ´æµããããã«LB1 (50mM HEPES-KOH pH7.5, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100)ã¨LB2 (10mM Tris-HCl pH 8.0, 200mM NaCl, 1mM EDTA, 0.5mM EGTA)ã§æ´æµãã
ãããããâ
ç´°èãlysis buffer (50mM Tris-HCl pH8.0, 10mMEDTA,1%SDS)ã§æ¸æ¿
ãããããâ
ç´°è溶解液ã¯Covaris S220ãç¨ãã¦å°è©¦é¨ç®¡ä¸ã§è¶
é³æ³¢ç ´ç ãã¦èª¿æ´ãduty cycle=5%, PIP=70, cycles per burst=200 ã®æ¡ä»¶ã§20åå¦ç
ãããããâ
ç´°è2Ã10^6åããã®ç´°è溶解液ãChIP dilution buffer (16.7mMTris-HCl pH8.0, 167mMNaCl, 1.2mMEDTA, 1.1%TritonX-100, 0.01% SDS)ã§å¸é
ãããããâ
ChIPã¯ãsheep æãã¦ã¹IgG beads (Invitrogen) ã¾ãã¯ãæhistone H3K4me3 æä½ (Wako, catalogue no. 307-34813)ãããã¯æhistoneH3K27me3 æä½(CST, catalogue no. 9733)ãçµåããã protein A beads (Invitrogen)ãç¨ãã
ãããããâ
ãã¼ãã¼ã¿ã¼ã§4âã«ã¦4ã6æéã¤ã³ãã¥ãã¼ã·ã§ã³
ãããããâ
ãã¼ãºãä½å¡©æ¿åº¦æ´æµãããã¡ã¼ (20mMTris HCl pH8.0, 150mM NaCl, 2mMEDTA, 1%Triton X-100, 0.1%SDS)ã§5åæ´æµ
ãããããâ
ãã¼ãºã好塩æ¿åº¦æ´æµãããã¡ã¼(20mM Tris-HCl pH8.0, 500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS)ã§3åæ´æµ
ãããããâ
æ¨çæè²ä½ã溶åºãããã¡ã¼(10mM Tris-HCl pH8.0, 300mM NaCl, 5mM EDTA, 1% SDS)ã§å®¤æ¸©ã«ã¦20å溶åº
ãããããâ
ã¯ãã¹ãªã³ã¯ã65âã§å¤ã
ãããããâ
試æãRNaseAã¨ãããã¤ã³ããã¼ã¼Kã§å¦ç
ãããããâ
調æ´ããDNA試æããã§ãã¼ã«ã»ã¯ãããã«ã æ½åºã§ç²¾è£½ããã¨ã¿æ²å¾ã«TEãããã¡ã¼ã§æº¶è§£
STAP幹細èã¸ã®è»¢æå¹é¤
STAPç´°èå¡ãMEF ãã£ã¼ãã¼ç´°èä¸ã«ACTHãå«ãå¹å°ã«ç§»ãï¼96ã¦ã§ã«ãã¬ã¼ãã®åã¦ã§ã«ã«ã¤ããæ°ã12åã®å¡ï¼
ãããããâ
4ã7æ¥å¾ãé常ã®ããªãã·ã³æ³ãç¨ãã¦æåã®ç¶ä»£ã20%FBSãå«ãESç¶æå¹å°ã«èã
ãããããâ
å¯éããåã«ãéæ¥ã«1:10ã®æ¯çã§åãã¦ç¶ä»£ãç¶ãã
ã»ç°ãªã3ã¤ã®éºä¼ããã¯ã°ã©ã¦ã³ããæã¤ãã¦ã¹ã§ãSTAPç´°èå¡ããSTAP幹細èã¸ã®è»¢æã調ã¹ãå¢æ®è½ã®ãã¼ã¿ãå¾ã
C57BL/6 carrying Oct4-gfp (29 of 29)
129/Sv carrying Rosa26-gfp (2 of 2)
129/SvÃC57BL/6 carrying cag-gfp (12 of 16)
3ã¤ã®éºä¼ããã¯ã°ã©ã¦ã³ããæã¤å ¨ã¦ã®ç³»çµ±ã§ãã¡ã©å½¢ææ´»æ§ã示ããã
[STAP幹細èã®ã¯ãã¼ã³è§£æ]
STAP幹細èãæä½æ¥ã§ç´°ãã¬ã©ã¹ããããã§æ¾ãã96ã¦ã§ã«ãã¬ã¼ãã«åã¦ã§ã«ã«ï¼åãã¤æ¤ãã
ããããâ
ã¯ãã¼ã³ã³ããã¼ã20%FBSãå«ãESå¹å°ã§å¹é¤
ããããâ
ããå¢æ®ããã
æ ¸å解æ
Multicolor FISH解æã§è¡ã
ãããâ
ã»ã¼å¯éããã¾ã§å¢ãããSTAP幹細èãã³ã«ã»ãã(æçµæ¿åº¦0.270 μg /ml)ãå¹å°ã«å
¥ãã¦åè£ä¸æã§åæ¢ãããã5%CO2ä¸ã§37â 2.5æé
ãããâ
ç´°èãPBSã§æ´æµããããªãã·ã³ã¨EDTAå¦ç
ãããâ
ç´°èå¹é¤æ¶²ã«åæ¸æ¿ãã5åé 1,200 r.p.m é å¿
ãããâ
æ²æ®¿ç©ã3mlã®PBSã«å
¥ããããããã温ãã¦ç½®ãã0.0375 M KCl溶液ãå ãã
ãããâ
ç´°èã37âã§20åéã¤ã³ãã¥ãã¼ããã
ãããâ
æ²æ®¿ç©ã3ã5 mlã®0.0375M KC1溶液ã«åæ¸æ¿
ãããâ
ç´°èãç©ããã«ããããã£ã³ã°ãã¦ã¡ã¿ãã¼ã«ï¼é
¢é
¸=3:1v/vã§åºå®
ãããâ
ç´°èãã¹ã©ã¤ãã°ã©ã¹ã«åºããåã«åºå®ã4åè¡ã
ãããâ
ãã¦ã¹æè²ä½ç¹ç°ççè²ããã¼ãã7ã¤ã®ç°ãªãèå
è²ç´ ã使ã£ã¦çµã¿åããã¦ã©ãã«
ãããâ
åè¿°ã®æ¹æ³ã§ãã¤ããªãã¤ãºãã
ãããâ
åç´°èç³»åã«ã¤ããSensys CCD(Photometrics)ã«ã¡ã©ãåããLeica DM RXA RF8è½å°èå
é¡å¾®é¡(Leica Mikrosysteme GmbH)ã使ã£ã¦9ã15ã®ä¸æã¹ãã¬ãããå¾ã
ã«ã¡ã©ã¨é¡å¾®é¡ã¯Leica Q-FISH software (Leica Microsystems)ã§ã³ã³ããã¼ã«
ãããâ
ä¸æã¹ãã¬ããã¯ãLeica MCKã½ããã¦ã§ã¢ã«åºã¥ãã¦å¦çããå¤è²æ ¸åã¨ãã¦è¡¨ããã
[Qãã³ã解æ]
Chromocentre (Japan)ã§è¡ã
ãããâ
ããã¯ãªã³ã§æè²å¾ãå試æãã20ç´°èãã©ã³ãã ã«é¸ã³ãæè²ä½ã®æ£å¸¸æ§ã解æ
ã»5ã¤ã®ç¬ç«ããSTAP幹細èã¯10ãããå¤ãç¶ä»£å¾ã®Qãã³ã解æã§æè²ä½ã®ç°å¸¸ã¯ç¤ºããªãã£ã